April 23, 2011 — Theralase Technologies Inc. announced that effective immediately, Brad Green, Kim Hillman, Derek McDonald, and Cliff Majni have been appointed as Territory Sales Managers – Therapeutic Division, reporting to Scott Bleue, National Sales Manager. Greg Bewsh has also been appointed as director of investor relations reporting to Roger Dumoulin-White, president and CEO.
Brad Green will be representing Theralase in the Southeast United States. He has more than 20 years of experience in the medical device industry with 14 years as a sales professional, which includes five years in a managerial role. He has sold to hospitals, physician offices, veterinary facilities, and acute care centers.
Kim Hillman will be representing Theralase in the Western United States. She has two years direct experience in therapeutic laser sales and more than eight years in the pharmaceutical industry. Throughout this time, Hillman has developed key relationships with thought leaders in the medical community across the Western United States.
Derek McDonald will be representing Theralase in Ontario. He has more than 23 years experience in sales, with 13 years in medical laser sales.
Cliff Majni will be representing Theralase in the Midwest United States. He has more than 15 years of sales experience in the pharmaceutical and medical equipment industries.
Greg Bewsh will be the new Director of Investor Relations for Theralase. He has more than 20 years’ experience in investor relations and financial services. He has advised clients with respect to strategic investor relations, corporate disclosure, governance, regulatory issues, raising capital, social media, and liquidity enhancement.
Previously, Bewsh acquired extensive experience as director of investor relations and corporate communications at two TSX and NASDAQ listed companies.
Roger Dumoulin-White, president and CEO of Theralase Technologies Inc., stated “I am excited by the quality of the new hires to our team, coming to us with significant experience in their respective fields. The improving US economy and the public’s desire for high efficacy, drug-free treatments in an aging population, is creating a significant opportunity for Theralase in 2011 and beyond. These new additions will support this vision.”
Source: Theralase, www.theralase.com